

PATENT

Attorney Docket No.: 15270-004300US
Client Reference No.: 00188-US-NEW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

S. A. Rubin et al.

Application No.: 09/010,377

Filed: January 21, 1998

For: TREATMENT OF VIRAL
ENCEPHALITIS BY AGENTS
BLOCKING ALPHA-VLA-4
INTEGRIN FUNCTION

Examiner: Philip Gambel

Art Unit: 1644

Communication Re Submission of
Declaration of Professor KarlikAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Further to the Preliminary Amendment filed on October 30, 2001, Applicants submit this document and the enclosed Declaration of Professor Stephen J. Karlik in the above-referenced matter. Applicants request consideration of these submissions during examination of the Continued Prosecution Application filed on March 27, 2001.

REMARKS

Professor Karlik is a renowned expert with extensive experience in the field of animal models for multiple sclerosis and other inflammatory disorders. In the enclosed declaration, Professor Karlik expressed his opinion regarding the differences between the animal model relied on by the present inventors and those discussed in the prior art cited in the Office Action in the parent application of this CPA, e.g., Bendig et al. (U.S. Patent No. 5,840,299), Soilu-Hanninen et al. (Scand. J. Immunol. 43: 727, 1996; "Soilu-Hanninen 1996"), and Soilu-Hanninen 1997 (J. Neuroimmunol. 72:95-105, 1997; "Soilu-Hanninen 1997"). In his expert opinion, Professor Karlik stated that (i) the animal model disclosed in the present